Cizzle Biotechnology Holdings PLC Sustainability Reports
Cizzle Biotechnology Holdings PLC operates as a diagnostics developer specializing in early cancer screening tests. The company focuses primarily on developing a non-invasive blood immunoassay test for early lung cancer detection using its patented CIZ1B biomarker technology.
Sector: Professional & technical services
Country: United Kingdom
Exchange: London Stock Exchange
LEI: 213800G3OS3SA2J1Y358
FIGI: BBG001SRRCZ3
5 reports from 2021 to 2025
